J P Morgan Chase & Co reaffirmed their hold rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a report issued on Thursday.

Several other research analysts also recently commented on the stock. UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a buy rating in a report on Friday, May 5th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a hold rating in a research note on Monday, May 15th. Piper Jaffray Companies raised their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an overweight rating in a research report on Tuesday, June 20th. Cowen and Company restated a hold rating and set a $380.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, May 15th. Finally, Sanford C. Bernstein restated an outperform rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 25th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $477.91.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.35% during trading on Thursday, reaching $468.76. The company had a trading volume of 771,168 shares. The company has a market capitalization of $49.49 billion, a price-to-earnings ratio of 56.74 and a beta of 1.66. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The company has a 50-day moving average price of $499.60 and a 200 day moving average price of $421.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the business posted $2.82 EPS. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $13.63 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Earns Hold Rating from J P Morgan Chase & Co” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/06/regeneron-pharmaceuticals-inc-regn-earns-hold-rating-from-j-p-morgan-chase-co.html.

In related news, Director Michael S. Brown sold 3,000 shares of the company’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $1,350,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Sanofi bought 136,050 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were bought at an average price of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 59,396 shares of company stock valued at $28,484,734. 10.40% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Jennison Associates LLC increased its stake in Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares during the last quarter. Janus Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the last quarter. Wellington Management Group LLP increased its stake in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Finally, Clearbridge Investments LLC increased its stake in Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares during the last quarter. 66.79% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.